Issued 2026-08-13 at $3.85 · now $3.73 (2026-08-13, −3.1% since)
Based on its own history, a month from the 2026-08-13 close, MNKD has typically landed between $3.12 and $4.89 — a range of −19.0% to +27.0% from the issuance price $3.85.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,978 overlapping 1 month windows · 2006-09-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($3.85) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where MNKD has typically landed a month from the 2026-08-13 close of $3.85 — the range is history, not a prediction.
- now $3.73 (-3.1%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.83 (-0.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.47–$4.18
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.12–$4.89
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2008-03-24 | −65.5% | −66.6% | +3.8% |
| 2008-03-27 | −65.2% | −67.6% | +0.8% |
| 2008-03-26 | −64.0% | −66.3% | +4.8% |
| 3 best | |||
| 2017-09-11 | +228.9% | −9.3% | +228.9% |
| 2017-09-08 | +169.2% | −6.6% | +169.2% |
| 2017-09-07 | +154.0% | −6.6% | +154.0% |
4,978 overlapping windows · 2006-09-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- March 2027 — Trial primary completion: Phase 2 primary completion: INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (source, as of 2026-08-14)
- 2028-01-30 — Trial primary completion: Phase 2 primary completion: Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.